The first oncolytic HSV-1 armed with GM-CSF, talimogene laherparepvec (T-VEC), demonstrated significant anti-tumor efficacy leading to FDA and EMA approval for melanoma therapy (71–73). The gene discussed is CSF2; the disease is neoplasm.